Hot Features
Premium
No photos found.
The CVR was awarded upon CHMP opinion not EC approval. But..it's only $5M in total.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
This user has no comment yet.
| No profile data added yet. |
No photos found.
The CVR was awarded upon CHMP opinion not EC approval. But..it's only $5M in total.
Does Mrs Claris Bemedicta advise buying Amryt? 😄😄😄
Oh great. That's worthless.in that case.
There are three CVRs. EMA, FDA and $75M revenue.The first two are time-bound but I think revenue is not. Happy to be corrected.
Ler's hope your broker will accept a dollar denominated cheque! :-)
An even bigger loss than the same quarter last year. Cash pile shrinking... Will Amryt ever be profitable?
No.
If you are interested in the format of the post-CRL meeting then here are the guidance notes..
Its unlikely that Amryt will be allowed to present any new data at the review meeting. I have listenned to enough CEO's with CRLs to know that Amryt
The PR states that the EMEA CVR is now payable but the value is not disclosed so we have to wait. The value was calculated on a sliding scale - max
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
